Evidence map›Paper›PMID 38236317›Full record

ArticleJournal of general internal medicine2024

Association Between Coronary Artery Disease Testing in Patients with New-Onset Heart Failure and Heart Failure Readmission and Mortality.

Cheng-Wei Huang, Siamak Kohan, In-Lu Amy Liu, Janet S Lee, Nicole C Baghdasaryan, Joon S Park, Jessica D Vallejo, Christopher C Subject, Huong Nguyen, Ming-Sum Lee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of general internal medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Cheng-Wei HuangDepartment of Hospital Medicine, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA. Cheng-wei.huang@kp.org.ORCID 0000-0002-7072-9679
Siamak KohanDepartment of Internal Medicine, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA.
In-Lu Amy LiuDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Janet S LeeDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Nicole C BaghdasaryanDepartment of Internal Medicine, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA.
Joon S ParkDepartment of Hospital Medicine, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA.
Jessica D VallejoDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Christopher C SubjectDepartment of Hospital Medicine, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA.
Huong NguyenDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Ming-Sum LeeDepartment of Clinical Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn patients with new-onset heart failure (HF), coronary artery disease (CAD) testing remains underutilized. Whether widespread CAD testing in patients with new-onset HF leads to improved outcomes remains to be determined.

objectiveWe sought to examine whether CAD testing, and its timing, among patients hospitalized with new-onset HF with reduced ejection fraction (HFrEF), is associated with improved outcomes.

designRetrospective cohort study.

participantsAdult (≥ 18 years) non-pregnant patients with new-onset HFrEF hospitalized within one of 15 Kaiser Permanente Southern California medical centers between 2016 and 2021. Key exclusion criteria included history of heart transplant, hospice, and a do-not-resuscitate order. MAIN MEASURES: Primary outcome was a composite of HF readmission or all-cause mortality through end of follow-up on 12/31/2022. KEY

resultsAmong 2729 patients hospitalized with new-onset HFrEF, 1487 (54.5%) received CAD testing. The median age was 66 (56-76) years old, 1722 (63.1%) were male, and 1074 (39.4%) were White. After a median of 1.8 (0.6-3.4) years, the testing group had a reduced risk of HF readmission or all-cause mortality (aHR [95%CI], 0.71 [0.63-0.79]). These results were consistent across subgroups by history of atrial fibrillation, diabetes, renal disease, myocardial infarction, and elevated troponin during hospitalization. In a secondary analysis where CAD testing was further divided to early (received testing before discharge) and late testing (up to 90 days after discharge), there was no difference in late vs early testing (0.97 [0.81-1.16]).

conclusionsIn a contemporary and diverse cohort of patients hospitalized with new-onset HFrEF, CAD testing within 90 days of hospitalization was associated with a lower risk of HF readmission or all-cause mortality. Testing within 90 days after discharge was not associated with worse outcomes.

Indexed as

Coronary Artery DiseaseHeart FailurePatient ReadmissionAgedCaliforniaFemaleHumansMaleMiddle AgedRetrospective Studies

Identifiers

PMID38236317
PMCPMC11043252

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.